NCT03081806已完成3 期
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Techfields Pharma Co. Ltd31 个研究点 分布在 1 个国家目标入组 399 人开始时间: 2021年9月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 399
- 试验地点
- 31
- 主要终点
- WOMAC pain subscale score in the target knee at Week 12 compared to Baseline
研究概览
简要总结
This is a Phase 3, Multicenter, 22-Week, double-blind and 30-Week open label Study to Evaluate the Efficacy and Safety of X0002 Spray in relief of pain of subjects with Osteoarthritis of the Knee.
详细描述
The study comprises a 14-day Screening Period, a 22-week Double-blind Treatment Period, and a 30-week Open-label Treatment Period, with an additional 4-week Follow-up Visit. Subjects will be randomized into a low-dose or high-dose group receiving either active or placebo treatment during the DB period.
The WOMAC version 3.1 using the NRS will be used for the primary and secondary efficacy endpoints. Safety assessments will include assessment of AEs, vital signs (blood pressure, respiratory rate, pulse rate, and oral temperature), clinical laboratory tests, physical examination, skin irritation, and electrocardiograms (ECGs).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 35 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to read and provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH GCP Guideline E6 and applicable regulations, before completing any study related procedures.
- •An understanding, ability, and willingness to fully comply with study procedures and restrictions.
- •Subject must be a male or female between 35 and 85 years of age, inclusive.
- •Female subjects must either not be of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or hysterectomy]) or be willing to Practice at least 1 of the following medically acceptable methods of birth control.
- •Subject must have a body mass index (BMI) between 18.5 and 45 kg/m2, inclusive.
- •Must have a history of clinically symptomatic OA of the knee for ≥6 months.
- •Must meet the American College of Rheumatology clinical classification criteria for knee OA. These criteria include the presence of knee pain in addition to at least 3 of the following 6 items:
- •age of ≥50 years
- •stiffness lasting <30 minutes
- •crepitus on knee motion
- •Bony Tenderness
- •Bony Enlargement
- •No palpable warmth
- •A subject must have a Kellgren Lawrence Grade of 2,3 or 4 as determined by a central radiologist at the first screening visit. .
- •Subject must have had knee pain while standing, walking, and/or in motion for at least 14 days during the month prior to Screening.
- •Subject must have a knee pain score ≥4 and <9 on 0-10 pain intensity NRS (without analgesic medication) on at least 7 of the 10 days prior to randomization.
- •Subject must be willing to discontinue any NSAIDs or other analgesic (eg, aspirin, acetaminophen) or potentially confounding concomitant treatments (eg, physiotherapy, acupuncture) starting on the first screening visit until completing participation in the study. (The use of ≤325 mg acetylsalicylic acid per day as cardiac prophylaxis is permitted.) The subject will be allowed to take rescue medication (acetaminophen) for pain during the study except during the 24 hours prior to the Second Screening Visit, Baseline (Day1), Week 2, Week 4, Week 8, Week 12, Week 22, Week 32, Week 42, and Week 52/EOS.
- •Subject must be willing to discontinue applying any topical preparations containing Vitamin A acids (including all trans retinoic acid (tretinoin), 13 cis retinoic acid [isotretinoin], 9 cis retinoic acid [alitretinoin], vitamin A [retinol], retinal, and their derivatives) to the lower limbs starting on the first screening visit until completing participation in the study. (Topical preparations containing Vitamin A acids or retinol may be applied to areas of the skin above the waist, but should not be applied to areas of the skin exposed to study medication.)
- •Subject must be willing to avoid unaccustomed physical activity (eg, starting a new weight lifting routine) for the duration of the study starting on the first screening visit.
- •With the exception of OA of the knee subjects with medical history must be stable as determined by the investigator.
排除标准
- •Has worker's compensation injuries affecting the knee or back.
- •Has a history of or is currently in litigation regarding joint injuries.
- •Has secondary OA of the target knee or OA of lower limb joints other than the knee that, in the investigator's opinion, could interfere with pain and functional assessments related to the target knee.
- •Has a history of total or partial knee replacement, arthroplasty, or other knee surgery on the target knee.
- •In the investigator's opinion, has had significant injury involving the target knee within the 6 months before Screening.
- •Has skin lesions or wounds on or near the target knee at Screening or at Baseline (Day 1) that, in the investigator's opinion, would affect absorption of the medication.
- •Has used opiates (including tramadol or tapentadol) or systemic corticosteroids within 30 days before Screening or requires treatment with chronic opiates or systemic corticosteroids.
- •Subjects with a placebo response exceeding 25% improvement in the average Western Ontario and McMaster Osteoarthritis Index [WOMAC] pain subscale score from Screening Visit to Day 1 will be excluded.
- •Has used gabapentin, pregabalin, antiepileptics, or specific antidepressants (i.e., tricyclics, serotonin norepinephrine reuptake inhibitors, or selective serotonin reuptake inhibitors) to treat pain in the 14 days before Screening. Other uses not related to the pain treatment may be permitted at the medical monitor's discretion provided they have been at a stable dose for at least 90 days.
- •Has had intra articular (IA) injections of corticosteroids, hyaluronic acid, or viscosupplements (e.g., Synvisc®) to the target knee within the 12 weeks before Screening
- •Has had IA or intravenous (IV) stem cell therapy in the 6 months prior to Screening
- •Is receiving or is planning to receive concomitant nonpharmacologic treatments (e.g., physiotherapy, acupuncture) that in the investigator's opinion could confound efficacy assessments within 14 days of Day
- •Has a history of significant hypersensitivity, intolerance, or allergy to ibuprofen or any other NSAIDs, aspirin, or acetaminophen.
- •Has had an active gastrointestinal (GI) ulceration in the 6 months prior to Screening or a history of GI bleeding within 5 years of Screening.
- •Has used an anticoagulant or antiplatelet agent (except aspirin up to 325 mg/day for cardiac prophylaxis) in the 30 days prior to Screening.
- •Has a documented history of chronic inflammatory disease (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, gouty arthritis) OR chronic pain condition (e.g., fibromyalgia), OR has other conditions that may affect the target joint for the functional and pain assessments (e.g., osteonecrosis, chondrocalcinosis).
- •Has uncontrolled depression or other uncontrolled psychiatric disorder (subjects with controlled depression or other psychiatric disorder, if using medication, must be on a stable dose of a medication other than an epileptic, tricyclic, serotonin norepinephrine reuptake inhibitor, or selective reuptake inhibitor for ≥12 weeks prior to Screening to participate in the study).
- •Has asthma requiring treatment with systemic corticosteroids in the last year prior to Screening. Asthmatic subjects using inhaled corticosteroids are eligible.
- •Has uncontrolled hypertension defined as systolic blood pressure >170 mmHg and diastolic blood pressure >90 mmHg at the Screening or Baseline Visit (may be repeated after 5 minutes rest to verify).
- •Is receiving systemic chemotherapy, has an active malignancy, lymphoproliferative disorder, or blood dyscrasia of any type, or has been diagnosed with cancer within 5 years before Screening. Subjects with completely excised squamous or basal cell carcinoma of the skin will be allowed.
- •Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, hepatic, or renal disease, or any other condition that, in the Investigator's opinion, could confound the study results, compromise the subject's welfare, interfere with the ability to communicate with the study staff, or otherwise contraindicate study participation.
- •Has any of the following conditions at Screening:
- •Acute hepatitis
- •Cirrhosis
- •Stage 4 or 5 end-stage renal disease
- •Subject has any other clinically significant laboratory finding at Screening that in the investigator's opinion contraindicates study participation.
- •Has clinically significant abnormality at Screening or Baseline (Day 1) on 12-lead ECG, including a QT interval calculated using Fridericia's correction (QTcF) interval >500 milliseconds (msec) or evidence of cardiac ischemia (i.e., Evident q waves: t wave inversion).
- •Is pregnant, planning to become pregnant during the study, or lactating. Has a positive serum and urine pregnancy test at Screening Visit, or a positive urine pregnancy test at Baseline (Day 1).
- •Has a positive urine drug screen for a nonprescribed drug prohibited by the protocol at Screening.
- •Has known alcohol or other substance abuse in the investigator's opinion.
- •Has participated in a previous clinical study with X
- •Has participated in any other clinical trial within the past 30 days or within 5 half-lives of the study drug prior to Screening, whichever is longer.
- •Is a participating investigator, sub-investigator, study coordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.
- •Has any factor that, in the investigator's opinion, would jeopardize the evaluation or safety or be associated with poor adherence to the protocol.
- •Is without access to telephone and/or ability to gain technology access.
研究组 & 干预措施
Group A
Experimental
High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
干预措施: X0002 (Drug)
Group B
Placebo Comparator
Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
干预措施: X0002 (Drug)
结局指标
主要结局
WOMAC pain subscale score in the target knee at Week 12 compared to Baseline
时间窗: Week 12
To evaluate the effect of X0002 spray compared to placebo for relief of knee pain in subjects with OA of the knee as measured by the WOMAC pain subscale score in the target knee at Week 12.
次要结局
- Average eDiary daily (NRS) score in the target knee(Week 2, 4, 8, 12 and 22 of treatment)
- WOMAC stiffness subscale(Week 2, 4, 8, 12 and 22 of treatment)
- WOMAC overall score(Week 2, 4, 8, 12 and 22 of treatment)
- Subject's Global Assessment of Disease Status at Week 12.(Week 12 of treatment)
- WOMAC fuctional subscale score in the target knee at Week 12(Week 12 of treatment)
- WOMAC (NRS) pain subscale in the target knee at Week 2, 4, 8, and 22(Week 2, 4, 8 , and 22 of treatment)
- WOMAC function subscale score(Week 2, 4, 8 , and 22 of treatment)
研究者
研究点 (31)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEHereditary Angioedema (HAE)NCT06669754Pharvaris Netherlands B.V.81
已完成
3 期
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPGeneralized Pustular PsoriasisNCT05352893Vanda Pharmaceuticals45
已完成
3 期
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)Candida VulvovaginitisNCT03734991Scynexis, Inc.376
已完成
3 期
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisCandida VulvovaginitisNCT03987620Scynexis, Inc.455
已完成
3 期
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAEHAEHereditary AngioedemaNCT03485911BioCryst Pharmaceuticals121